Ginkgo Bioworks Holdings (DNA) Long-Term Investments (2020 - 2026)

Ginkgo Bioworks Holdings (DNA) has reported Long-Term Investments for 7 consecutive years, with $14.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Long-Term Investments fell 54.76% year-over-year to $14.8 million; the trailing twelve-month figure through Jun 2026 stood at $14.8 million (down 54.76% YoY), and the FY2025 full-year result was $15.1 million, down 69.07% from the prior year.
• Long-Term Investments was little changed at $14.8 million in Q2 2026 per DNA's latest filing, from $14.7 million in the prior quarter.
• Across five years, Long-Term Investments topped out at $121.8 million in Q1 2023 and bottomed at $14.7 million in Q1 2026.
• Historically, Long-Term Investments has averaged $66.4 million across 5 years, with a median of $69.3 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Long-Term Investments slumped 94.84% in 2022, then jumped 34.67% in 2023.
• Over 5 years, Long-Term Investments stood at $112.2 million in 2022, then fell by 29.97% to $78.6 million in 2023, then plunged by 38.01% to $48.7 million in 2024, then sank by 69.07% to $15.1 million in 2025, then dropped by 1.93% to $14.8 million in 2026.
• According to Business Quant data, Long-Term Investments over the past three periods registered $14.8 million, $14.7 million, and $15.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.